Patent Yard Sign in
Expired European patentEurope

Peptides of the tsp-1 receptor cd36 for the treatment of diseases caused by a dysregulation of tgf-beta1

EP 0827407 B1 · Applicant: MANITOBA CANCER TREATMENT AND RESEARCH FOUNDATION

EPO PDF

Overview

The published document from the EPO: abstract, claims, description and drawings. Open it full size

Read the whole patent

Listed from its EPO record in Patent Yard's archive of European patents past their term. Its claims, description and drawings are in the EPO PDF and on Google Patents, and the Claude kit works from them.

Google PatentsEPO PDF

Why it's free to use

  • Filed May 17, 1996 and granted April 6, 2005. A European patent lasts at most 20 years from filing, so its term ended May 17, 2016.
  • A supplementary protection certificate, which can extend a medicine or crop-protection patent, adds at most five and a half years, so even that would have ended by November 17, 2021.
  • We check European rights only. A US or other national patent in its family could still be in force: check its family on Espacenet or Google Patents.
FiledMay 17, 1996
PublishedMarch 11, 1998
GrantedApril 6, 2005
Term endedMay 17, 2016
Application numberEP 96914810
Classification (CPC)C07K14/705 +1 more

Timeline

Timeline From EPO dates

1997199920012003200520072009201120132015Application filedMay 17, 1996PublishedMarch 11, 1998Patent grantedApril 6, 2005Term endedMay 17, 2016

Sources & verification

Official EPO records

Full published documentClaims, description and drawings as a PDF.EPOEuropean Patent RegisterProcedure, status, file inspection and legal events.EPOLinked open EP data recordThe bibliographic record this page is built from.EPO

Cross-check elsewhere

Google PatentsFull text, worldwide family, citing patents and legal events.patents.google.comEspacenetNational family members and their legal status.European Patent Office

Everything on this page comes from the EPO record linked above. EPO data used under CC BY 4.0.